Article content
The study was based on a U.S. health database, and so did not accrue new data on the risk of clots from AstraZeneca’s vaccine directly, as the shot is not being rolled out there.
Taquet said that the mortality rate from CVST was around 20% whether it occurred after COVID-19 infection or a vaccine, indicating the clots were the main risk factor.
Regulators had also observed low platelet levels in reports of vaccine side effects, but the researchers said data was limited on whether that was also the case in those reporting CVST after infection.
The researchers highlighted that COVID-19 was associated with more common clotting disorders than CVST, such as strokes, and that recent debate around vaccines had lost sight of how bad the disease itself could be.